Biogen Idec (BIIB +1.6%) says new data from Phase III studies evaluating its experimental...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen Idec (BIIB +1.6%) says new data from Phase III studies evaluating its experimental multiple-sclerosis pill BG-12 showed strong clinical and positive radiological effects in people with relapsing-remitting MS. The data was presented at the 28th Congress of the European Committee for the Treatment and Research of Multiple Sclerosis in Lyon, France.